ESSA Pharma Inc EPIX

Healthcare Biotechnology

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

NDAQ:EPIX - Post by User

ESSA Pharma Inc

Bullboard Posts

Comment by SergioDon Jan 17, 2018 5:29pm

118 Views

Post# 27380703

RE:EPI on Watch Zone

Great price movement today. With the 6 month extension, I think we can expect some news to try and push SP to $1.00 on the US side (or about $1.20-$1.30 on the TSXV) to maintain their Nasdaq listing.

Bullboard Posts

New CEO leads Sonoro Energy's vision to expand in MENA